Seller record · Telehealth service

eMed

By Peptide Alliance, Editorial publisherRecorded October 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: No filling facility is identified in the home, individual program, support and privacy-practice pages reviewed. 1 more criterion also fails; see the table below.

At a glance

eMedTelehealth service

4/8criteria passed

Price: Not yet recorded
Sells: Wegovy, Zepbound
FDA letters: None on file

Visit eMed See all eight dispositions

Telehealth service. Passes 4 of 8 criteria. 2 not verified, counting neither way. Recorded against Standard v1.1.

A GLP-1 care program for individuals and employers that combines clinician consultations, diagnostic support and follow-up care, with FDA-approved medication subject to eligibility and prescribing decisions.

Operating entity eMed Population Health, Inc.

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	eMed's join page
S2	Prescription gating	NOT VERIFIED	eMed's join page
S3	Pharmacy identification	FAIL	eMed's join page
S4	Compounding disclosure	PASS	eMed's join page
S5	Analytical documentation	FAIL	eMed's website
S6	Business address	PASS	eMed's privacy practices notice
S7	Price disclosure	NOT VERIFIED	eMed's join page
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSPublic individual program requires consultation with a licensed clinician; prescription is not guaranteed.Source: eMed's join page.

S2NOT VERIFIEDThe public criterion check did not resolve, because public individual program makes medication subject to clinician consultation and eligibility; the payment-versus-evaluation sequence is not resolved. The check is open.Source: eMed's join page.

S3FAILNo filling facility is identified in the home, individual program, support and privacy-practice pages reviewed.Source: eMed's join page.

S4PASSPublic program describes FDA-approved GLP-1 options and provides branded prescribing information.Source: eMed's join page.

S5FAILNo reachable lot-specific analytical certificate is published in the home, contact, legal and public program pages examined.Source: eMed's website.

S6PASSPrivacy-practice notice gives 990 Biscayne Boulevard, Suite 1501, Miami, Florida 33132 for eMed Population Health, Inc.Source: eMed's privacy practices notice.

S7NOT VERIFIEDThe public criterion check did not resolve, because the individual program prints $49 and $149.99 components, but the relationship between support cost, medication cost and plan duration needs clarification before a total-price comparison. The check is open.Source: eMed's join page.

S8PASSNo FDA warning letter names eMed Population Health, Inc., and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: Wegovy, Zepbound.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit eMed

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.